| Ortega-Deballon P, Facy O, Rat P
A "happy marriage" between open and closed techniques of heated intraperitoneal chemotherapy. [Journal Article]
Cancer J 2009 Sep-Oct; 15(5):448.
Full Citation | Publisher Full Text | Find Related Articles |
| Esquivel J, Sugarbaker PH
A "happy marriage" between open and closed techniques of heated intraperitoneal chemotherapy. [Journal Article]
Cancer J 2009 Sep-Oct; 15(5):448-9.
Full Citation | Publisher Full Text | Find Related Articles |
| Stein WD, Huang H, Menefee M, et al.
Other paradigms: growth rate constants and tumor burden determined using computed tomography data correlate strongly with the overall survival of patients with renal cell carcinoma. [Journal Article]
Cancer J 2009 Sep-Oct; 15(5):441-7.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |
| Trask PC, Hsu MA, McQuellon R
Other paradigms: health-related quality of life as a measure in cancer treatment: its importance and relevance. [Journal Article]
Cancer J 2009 Sep-Oct; 15(5):435-40.
Abstract | Full Citation | Publisher Full Text |
| Stadler W
Other paradigms: randomized discontinuation trial design. [Journal Article]
Cancer J 2009 Sep-Oct; 15(5):431-4.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |
| Sharma MR, Maitland ML, Ratain MJ
Other Paradigms: Better Treatments Are Identified by Better Trials: The Value of Randomized Phase II Studies. [Journal Article]
Cancer J 2009 Sep-Oct; 15(5):426-30.
Abstract | Full Citation | Publisher Full Text |
| Buyse M
Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials. [Journal Article]
Cancer J 2009 Sep-Oct; 15(5):421-5.
Abstract | Full Citation |
| Tan DS, Thomas GV, Garrett MD, et al.
Biomarker-Driven Early Clinical Trials in Oncology: A Paradigm Shift in Drug Development. [JOURNAL ARTICLE]
Cancer J 2009 September/October; 15(5):406-420.
Abstract | Full Citation |
| Driscoll JJ, Rixe O
Overall survival: still the gold standard: why overall survival remains the definitive end point in cancer clinical trials. [Journal Article]
Cancer J 2009 Sep-Oct; 15(5):401-5.
Abstract | Full Citation |
| Zhuang SH, Xiu L, Elsayed YA
Overall survival: a gold standard in search of a surrogate: the value of progression-free survival and time to progression as end points of drug efficacy. [Journal Article]
Cancer J 2009 Sep-Oct; 15(5):395-400.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |
  |
